FDA accepts investigational new drug application for phase 2 trial of NT-503 encapsulated cell therapy

The FDA has accepted an investigational new drug application for a phase 2 clinical study of NT-503 encapsulated cell therapy for the treatment of recurrent subfoveal choroidal neovascularization secondary to age-related macular degeneration, Neurotech Pharmaceuticals announced in a press release. NT-503 is a VEGF receptor protein continuously produced by the encapsulated cell therapy platform.